Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Ciena (CIEN) -- Ignore unavailable to you. Want to Upgrade?

To: jghutchison who wrote (9737)	10/27/2000 12:21:08 PM
From: Raymond Duray	Read Replies (1) \| Respond to of 12623

Jack, Velio is velly, velly real, IMO. CIEN and SCMR are already designing line cards and shipping them with slots for the new Velio chip. It's a bit over my pay scale to describe what they do, but suffice it to say the idea is that one Velio uberchip replaces about a dozen PMCS type framers, clocks, etc. on one device. Anytime I see an order of magnitude advance like that I tend to pay attention. Hyperchip's network processor has been proven in FPGA prototype and the ASICs are being taped now. I'm not sure who the customer base is, or how easily the device will be incorporated into systems. I keep an eye out for news, but haven't seem much lately. AFAIK, the company is legit and the product will be real. Still hunting for the customers though. Hyperchip is working at and beyond OC-768. Re: CRA - Paracel is a supercomputer company that is a wholly owned subsidiary of CRA. Venter was recently quoted as saying that IBM's recently announced initiative to spend $100M on a competing supercomputer for genome and proteome sequencing is a total waste of money. Strong words from a partisan, but Dr. Venter knows whereof he speaks and if I were IBM, I'd thing again. If the boys at Motley Fool and Porter Stansbury are to be believed, Paracel is the most advanced computer manufacturer specifically geared to biomedical research. It is a good thing the NIH is doing the job right, and their info is free for the asking. Better too. Venter agrees, the genome data should be freely available. In what sense do you mean that the NIH data is better? More complete? More useful? More easily manipulated and parsed? It is only more complete. CRA wins hands down on the latter two questions. Bon Chance, Ray